Johnson & Johnson (NYSE:JNJ) Stock, Quote.Headers.trade-ideas

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Cancer-Image by PDPics from Pixabay-

Biotech

Equities

Large Cap

News

Health Care

General

Johnson &amp; Johnson&#39;s Rybrevant (amivantamab) received FDA approval for use with standard chemotherapy in advanced non-small cell lung cancer with specific EGFR mutations.

Johnson &amp; Johnson&#39;s Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients

zvra

ZVRA

The FDA has approved Zevra Therapeutics&#39; Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic Metabolic Diseases Advisory Committee.

Zevra Therapeutics&#39; Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease

biotech shutter

Price Target

Initiation

Analyst Ratings

BGNE

JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a &#39;unique investment opportunity.&#39; The firm&#39;s leading drug, Brukinsa (zanubrutinib), is emerging in the competitive BTK inhibitor market.

Chinese Biotech BeiGene Labeled &#39;Unique Investment&#39; As Analyst Confident In Lead Cancer Drug

Legal

Johnson & Johnson Announced That Its Subsidiary, Red River Talc Has Filed A Voluntary Prepackaged Chapter 11 Case To Resolve All Current And Future Ovarian Cancer Talc Claims

Thursday, the FDA approved Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Rybrevant&nbsp;(amivantamab-vmjw) in combination with standard-of-care chemotherapy (carboplatin and pemetrexed) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40949916/rybrevant-amivantamab-vmjw-plus-standard-of-care-approved-in-the-u-s-as-first-and-only-targeted-re" rel="noreferrer noopener">tyrosine kinase inhibitor</a>.
The FDA approval is based on results from the Phase 3 MARIPOSA-2 study, which showed that Rybrevant&nbsp;plus chemotherapy reduced the risk of disease progression or death (progression-free survival [PFS]) by 52% compared to chemotherapy alone, the study&#8217;s primary endpoint.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40630058/johnson-johnson-seeks-fda-approval-for-muscle-weakness-drug-and-gears-up-showdown-with-argenx-and" rel="noreferrer noopener">Johnson &amp; Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB</a>.
The median PFS for patients receiving Rybrevant&nbsp;plus chemotherapy was 6.3 months, compared to 4.2 months for chemotherapy alone.
Additionally, Rybrevant plus chemotherapy showed a confirmed overall response rate (ORR) of 53% compared to 29% with chemotherapy alone.
This approval marks the third new indication for Rybrevant&nbsp;this year,&nbsp;following the&nbsp;FDA&nbsp;<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4248839-1&amp;h=2533596364&amp;u=https%3A%2F%2Fwww.jnj.com%2Fmedia-center%2Fpress-releases%2Frybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-approved-in-the-u-s-as-a-first-line-chemotherapy-free-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer&amp;a=approval" rel="noreferrer noopener">approval</a> of Rybrevant&nbsp;in combination with Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or&nbsp;L858R substitution mutations, based on the Phase 3 MARIPOSA study, and FDA&nbsp;<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4248839-1&amp;h=2687046947&amp;u=https%3A%2F%2Fwww.jnj.com%2Fmedia-center%2Fpress-releases%2Frybrevant-amivantamab-vmjw-in-combination-with-chemotherapy-is-the-first-fda-approved-therapy-for-first-line-treatment-of-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations&amp;a=approval" rel="noreferrer noopener">approval</a> of Rybrevant&nbsp;in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, based on the Phase 3 PAPILLON study.
In June, Johnson &amp; Johnson submitted an FDA marketing application for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration for all currently approved or submitted indications of intravenous (IV) Rybrevant.
The application is based on the Phase 3 PALOMA-3 study, in which the preliminary results showed a five-fold reduction in infusion-related reactions (IRR) with a five-minute administration of SC amivantamab.
Price Action: JNJ stock is down 0.18% at $164.52 at last check Friday.
Image by PDPics from Pixabay
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40958885/vinfast-hits-roadblock-fails-to-meet-q2-earnings-and-sales-expectations-cautions-on-challenging-mac" target="_blank" rel="noreferrer noopener">VinFast Hits Roadblock: Fails To Meet Q2 Earnings And Sales Expectations, Cautions On Challenging Macro EV Outlook</a>.</li>
</ul>

Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients

Friday, the FDA approved &nbsp;Zevra Therapeutics, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) Miplyffa (arimoclomol), an oral medication for Neimann-Pick disease, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40961665/zevra-therapeutics-miplyffa-arimoclomol-receives-u-s-fda-approval-as-treatment-for-niemann-pick-di" rel="noreferrer noopener">type C (NPC)</a>.
Miplyffa, in combination with Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) enzyme inhibitor Zavesca (miglustat), is approved to treat neurological symptoms associated with NPC in adults and children two years of age and older.
Miplyffa is the first drug approved by the FDA to treat NPC.&nbsp;
NPC is a rare genetic disease that results in progressive neurological symptoms and organ dysfunction.
It is caused by changes in either the NPC1 or NPC2 gene, affecting the necessary transport of cholesterol and other lipids within a cell. As a result, these cells do not function as they should, ultimately causing organ damage.
Miplyffa was the first product application to be&nbsp;discussed&nbsp;at the inaugural meeting of the&nbsp;Genetic Metabolic Diseases Advisory Committee&nbsp;(GeMDAC) in August.
The committee voted favorably (11 yes, 5 no) that the data supports that arimoclomol is effective in treating <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40157788/fda-panel-backs-zevras-arimoclomol-for-rare-genetic-disorder-analyst-highlights-bal" rel="noreferrer noopener">patients with NPC</a>.
GeMDAC was established in December 2023 to advise the agency on products used for the diagnosis, prevention or treatment of genetic metabolic diseases.&nbsp;
The safety and effectiveness of Miplyffa were evaluated in a randomized, double-blind, placebo-controlled 12-month trial in patients.
Miplyffa's efficacy was demonstrated by the rescored 4-domain NPC Clinical Severity Scale (R4DNPCCSS) score in the patients who used miglustat as their background treatment.
The R4DNPCCSS is a measure of NPC disease progression. Higher scores signify a greater severity of the disease.
Compared to placebo, Miplyffa resulted in a slower disease progression.
In 2021, the FDA issued a complete response letter to arimoclomol as a treatment option for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/21/06/21621339/orphazyme-wild-party-at-risk-as-fda-rejects-its-rare-neurodegenerative-disease-drug?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29" rel="noreferrer noopener">Niemann-Pick disease type C</a>.
The CRL asked for additional qualitative and quantitative evidence to further support the validity and interpretation of the 5-domain NPC Clinical Severity Scale,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/21/11/23783862/orphazyme-stock-gains-after-fda-update-on-arimoclomol-in-rare-neurodegenerative-disorder" rel="noreferrer noopener">particularly the swallow domain</a>.
Zevra Therapeutics resubmitted its New Drug Application (NDA) for arimoclomol to the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/23/12/g36395563/zevra-therapeutics-announces-resubmission-of-arimoclomol-new-drug-application-to-the-u-s-food-and-" rel="noreferrer noopener">FDA in December 2023</a>.
Price Action: ZVRA stock is up 1.01% at $8.01 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40961934/novo-nordisk-stock-declines-after-headline-results-from-mid-stage-study-of-monlunabant-in-obese-p" target="_blank" rel="noreferrer noopener">Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients</a>.</li>
</ul>

Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease

RBC Capital analyst Shagun Singh reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and maintains $175 price target.

Reiteration

RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target

Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking&nbsp;the third new indication for RYBREVANT&reg;&nbsp;this year, with four indications overall

Johnson & Johnson Announces FDA Approval Of RYBREVANT Plus Chemotherapy As The First Targeted Therapy To Halve Disease Progression Risk In Second-Line EGFR-Mutated Lung Cancer

Across the recent three months, 14 analysts have shared their insights on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $194.93, a high estimate of $215.00, and a low estimate of $150.00. A 0.83% drop is evident in the current average compared to the previous average price target of $196.57. 
<img src="https://www.benzinga.com/files/images/story/2024/1726776114_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Johnson &amp; Johnson by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Narumi Nakagiri</td>
<td>Daiwa Capital</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$155.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$169.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Johnson &amp; Johnson. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Johnson &amp; Johnson's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Johnson &amp; Johnson's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>About Johnson &amp; Johnson</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Financial Milestones: Johnson &amp; Johnson's Journey</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Johnson &amp; Johnson displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 4.31%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Johnson &amp; Johnson's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 20.88%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Johnson &amp; Johnson's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 6.62%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.65%, the company showcases effective utilization of assets.
Debt Management: Johnson &amp; Johnson's debt-to-equity ratio is below the industry average. With a ratio of 0.58, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Johnson & Johnson

Cantor Fitzgerald analyst Louise Chen reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Overweight and maintains $215 price target.

Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

JMP Securities initiated coverage on BeiGene Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>), noting the Chinese biotech firm as a &#8216;unique <a target="_blank" href="https://www.benzinga.com/quote/bgne" rel="noreferrer noopener">investment opportunity</a>.&#8217;
The company&#8217;s flagship drug, Brukinsa (zanubrutinib), is among the more recent BTK inhibitors to break into a global market projected to hit $12.2 billion by 2031. Three major players dominate this sector, with Johnson &amp; Johnson&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Imbruvica leading the charge, peaking at $8.7 billion in sales in 2021.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534057/cancer-medicines-from-merck-bristol-myers-and-beigene-in-question-as-fda-committee-to-discuss-lim" rel="noreferrer noopener">Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer</a>.
However, competition intensified when AstraZeneca Plc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Calquence and Brukinsa entered the market in 2017 and 2019, respectively.
Analyst Reni Benjamin&#8217;s confidence in Brukinsa emerging as a market leader is bolstered by an exclusive survey of 37 doctors, indicating that 80% plan to boost their use of Brukinsa due to its perceived safety and long-term <a href="https://www.benzinga.com/general/biotech/24/03/37560438/fda-conditionally-approves-expanded-use-of-beigenes-combination-drug-for-certain-type-of-blood-ca" target="_blank" rel="noreferrer noopener">effectiveness advantages</a>.
As Imbruvica&#8217;s popularity declines, Calquence and Brukinsa will capture a larger market share. By 2031, Brukinsa is expected to command 55% of the market, potentially generating global sales of $5.4 billion, the analyst adds.
Benjamin says Brukinsa is on track to generate over $2 billion for the company in 2024, with total revenues to reach $3.7 billion.
The analyst has initiated the coverage with a Market Perform rating and a <a target="_blank" href="https://www.benzinga.com/quote/BGNE/analyst-ratings" rel="noreferrer noopener">price target of $288</a>.
China ranks as the third-largest healthcare market globally, behind the U.S. and the EU, with expenditures reaching $1.2 trillion.
BeiGene, which offers 14 products in China through various U.S. partners, holds a significant position in this market. Despite limited visibility into China&#8217;s regulatory and commercial environment, BeiGene&#8217;s sales force has driven annual revenues from China to $1.1 billion.
However, JMP writes that the numbers can drop to $178 million by 2031 due to patent expirations unless additional therapeutics are licensed.
Price Action: BGNE stock is up 1.05% at $199.59 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40924917/veea-partners-with-iot-platform-crowdkeep-whats-the-benefit" target="_blank" rel="noreferrer noopener">Veea Partners With IoT Platform Crowdkeep &#8211; What&#8217;s The Benefit?</a></li>
</ul>
Photo: Shutterstock

Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug

&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT&#xAE; (amivantamab-vmjw) combined with chemotherapy (mFOLFOX6 [FOLFOX] or FOLFIRI) demonstrated promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not previously received anti-epidermal growth factor receptor (EGFR) therapy. These data were presented in a mini-oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4252540-1&amp;h=2665487340&amp;u=https%3A%2F%2Fwww.esmo.org%2Fmeeting-calendar%2Fesmo-congress-2024&amp;a=European+Society+of+Medical+Oncology+(ESMO)+2024+Congress">European Society of Medical Oncology (ESMO) 2024 Congress</a>.1
 &nbsp;

Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)&nbsp;announced today additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy profile of investigational TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC). New data were featured in a late-breaking oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4254490-1&amp;h=622561329&amp;u=https%3A%2F%2Fwww.esmo.org%2Fmeeting-calendar%2Fesmo-congress-2024&amp;a=European+Society+of+Medical+Oncology+(ESMO)+2024+Congress">European Society of Medical Oncology (ESMO) 2024 Congress</a>&nbsp;(Abstract #LBA85).
 &nbsp;

Reported Sunday, Johnson & Johnson Reveals New Data on TAR-200 for Bladder Cancer Treatment

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today interim data from the ongoing Phase 2 SunRISe-4 study showing neoadjuvant treatment with investigational TAR-200 plus cetrelimab (CET) achieved nearly double the pathological complete response (pCR) rate compared to CET alone in patients with muscle-invasive bladder cancer (MIBC) who are ineligible or refuse neoadjuvant platinum-based chemotherapy and scheduled for radical cystectomy (RC).1 These data were featured as a late-breaking oral presentation at the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4254648-1&amp;h=1630264785&amp;u=https%3A%2F%2Fwww.esmo.org%2Fmeeting-calendar%2Fesmo-congress-2024&amp;a=European+Society+of+Medical+Oncology+(ESMO)+2024+Congress">European Society of Medical Oncology (ESMO) 2024 Congress</a> (Abstract #LBA84).

Johnson & Johnson's TAR-200 Plus Cetrelimab Nearly Doubles Cancer Response Rate in Bladder Cancer Phase 2 Trial

Whales with a lot of money to spend have taken a noticeably bullish stance on Johnson &amp; Johnson.
Looking at options history for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 30% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $552,410 and 5, calls, for a total amount of $522,817.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $155.0 to $170.0 for Johnson &amp; Johnson over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Johnson &amp; Johnson's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Johnson &amp; Johnson's whale activity within a strike price range from $155.0 to $170.0 in the last 30 days. 
<h3>Johnson &amp; Johnson 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726174159_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.65</td>
<td>$4.55</td>
<td>$4.56</td>
<td>$160.00</td>
<td>$410.4K</td>
<td>4.8K</td>
<td>1.2K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$15.7</td>
<td>$15.15</td>
<td>$15.59</td>
<td>$155.00</td>
<td>$144.9K</td>
<td>7</td>
<td>93</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.5</td>
<td>$13.45</td>
<td>$13.45</td>
<td>$155.00</td>
<td>$121.0K</td>
<td>3.3K</td>
<td>114</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$13.7</td>
<td>$12.75</td>
<td>$13.7</td>
<td>$160.00</td>
<td>$119.1K</td>
<td>1.4K</td>
<td>87</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$10.65</td>
<td>$9.4</td>
<td>$9.6</td>
<td>$170.00</td>
<td>$80.6K</td>
<td>8</td>
<td>95</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
After a thorough review of the options trading surrounding Johnson &amp; Johnson, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Johnson &amp; Johnson's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,494,400, the price of JNJ is down by -0.11%, reaching $164.64.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 33 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Johnson &amp; Johnson</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $215.0.
<ul>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $215. </li>
<li>Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $215.</li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Johnson &amp; Johnson with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Unpacking the Latest Options Trading Trends in Johnson & Johnson

In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) in comparison to its major competitors within the Pharmaceuticals industry. By analyzing crucial financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
<h3>Johnson &amp; Johnson Background</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson &amp; Johnson</td>
<td>24.93</td>
<td>5.55</td>
<td>4.68</td>
<td>6.62%</td>
<td>$7.8</td>
<td>$15.58</td>
<td>4.31%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>113.41</td>
<td>61.14</td>
<td>21.38</td>
<td>22.5%</td>
<td>$4.12</td>
<td>$9.13</td>
<td>35.98%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>45.54</td>
<td>36.18</td>
<td>15.87</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc</td>
<td>21.24</td>
<td>6.67</td>
<td>4.68</td>
<td>13.0%</td>
<td>$7.45</td>
<td>$12.37</td>
<td>7.16%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>39.09</td>
<td>6.32</td>
<td>5.12</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>23.57</td>
<td>5.59</td>
<td>4.87</td>
<td>7.97%</td>
<td>$5.25</td>
<td>$9.7</td>
<td>9.6%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>30.99</td>
<td>1.80</td>
<td>2.76</td>
<td>1.53%</td>
<td>$2.03</td>
<td>$7.97</td>
<td>6.53%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>14.84</td>
<td>4.75</td>
<td>1.92</td>
<td>8.32%</td>
<td>$2.31</td>
<td>$5.76</td>
<td>9.84%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>37.25</td>
<td>17.33</td>
<td>9.78</td>
<td>12.45%</td>
<td>$0.97</td>
<td>$1.69</td>
<td>8.3%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>45.16</td>
<td>0.86</td>
<td>1.53</td>
<td>1.26%</td>
<td>$388.51</td>
<td>$821.04</td>
<td>14.11%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>19.97</td>
<td>3.76</td>
<td>3.85</td>
<td>4.84%</td>
<td>$21.72</td>
<td>$46.34</td>
<td>13.87%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>17.82</td>
<td>1.73</td>
<td>1.88</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>5.20</td>
<td>36.05</td>
<td>0.82</td>
<td>203.12%</td>
<td>$0.43</td>
<td>$0.94</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>31.46</td>
<td>6.23</td>
<td>6.91</td>
<td>6.14%</td>
<td>$0.04</td>
<td>$0.16</td>
<td>39.15%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>17.39</td>
<td>2.10</td>
<td>3.21</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>33.07</td>
<td>13.61</td>
<td>6.04</td>
<td>22.33%</td>
<td>$33.8</td>
<td>$70.34</td>
<td>13.27%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>After examining Johnson &amp; Johnson, the following trends can be inferred: 
<ul>
<li>
A Price to Earnings ratio of 24.93 significantly below the industry average by 0.75x suggests undervaluation. This can make the stock appealing for those seeking growth.
</li>
<li>
The current Price to Book ratio of 5.55, which is 0.41x the industry average, is substantially lower than the industry average, indicating potential undervaluation.
</li>
<li>
Based on its sales performance, the stock could be deemed undervalued with a Price to Sales ratio of 4.68, which is 0.77x the industry average.
</li>
<li>
The Return on Equity (ROE) of 6.62% is 15.71% below the industry average, suggesting potential inefficiency in utilizing equity to generate profits.
</li>
<li>
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.8 Billion is 0.23x below the industry average, suggesting potential lower profitability or financial challenges.
</li>
<li>
Compared to its industry, the company has lower gross profit of $15.58 Billion, which indicates 0.22x below the industry average, potentially indicating lower revenue after accounting for production costs.
</li>
<li>
The company's revenue growth of 4.31% is significantly below the industry average of 13.27%. This suggests a potential struggle in generating increased sales volume.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726153246_0_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio helps evaluate the capital structure and financial leverage of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When evaluating Johnson &amp; Johnson alongside its top 4 peers in terms of the Debt-to-Equity ratio, the following insights arise:
<ul>
<li>
In terms of the debt-to-equity ratio, Johnson &amp; Johnson has a lower level of debt compared to its top 4 peers, indicating a stronger financial position.
</li>
<li>
This implies that the company relies less on debt financing and has a more favorable balance between debt and equity with a lower debt-to-equity ratio of 0.58.
</li>
</ul>
<h3>Key Takeaways</h3>
For Johnson &amp; Johnson in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to its peers, indicating potential undervaluation. However, the low ROE, EBITDA, gross profit, and revenue growth suggest underperformance relative to industry standards. This may signal a need for further investigation into the company's operational efficiency and growth strategies.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Competitor Analysis: Evaluating Johnson &amp; Johnson And Competitors In Pharmaceuticals Industry

Government

Regulations

Johnson & Johnson Seeks First EU Approval Of Nipocalimab To Treat Broad Population Of Patients Living With Antibody-positive Generalised Myasthenia Gravis

On Tuesday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions (IRRs) with intravenous (IV) Rybrevant (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or <a href="https://www.benzinga.com/general/biotech/24/09/40813730/johnson-johnsons-mid-stage-lung-cancer-trial-reveals-fewer-infusion-related-reactions">L858R substitution mutations.</a>
The company, last month, agreed to acquire V-Wave for an upfront payment of $600 million, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion.
With the recent buzz around Johnson &amp; Johnson, some investors may be eyeing potential gains from the company's dividends too. As of now, Johnson &amp; Johnson offers an annual dividend yield of 3.01%. That&#8217;s a quarterly dividend amount of $1.24 per share ($4.96 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $199,432 or around 1,210 shares. For a more modest $100 per month or $1,200 per year, you would need $39,886 or around 242 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.96 in this case). So, $6,000 / $4.96 = 1,210 ($500 per month), and $1,200 / $4.96 = 242 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
JNJ Price Action: Shares of Johnson &amp; Johnson fell 1.5% to close at $164.82 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well"> </a>
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well">Jim Cramer: &#8216;Not The Time To Own Oil,&#8217; When Asked About Exxon Mobil; Says IBM Is &#8216;Performing Well&#8217;</a></li>
</ul>

Earnings

Long Ideas

How To Earn $500 A Month From Johnson & Johnson Stock

<ul>
<li>The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA&reg;&nbsp;showed&nbsp;highly&nbsp;statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program1,2,3,4,5</li>
<li>TREMFYA&reg;&nbsp;is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis</li>
</ul>

Reported Earlier, FDA Approves Johnson & Johnson's TREMFYA For Adults With Moderately To Severely Active Ulcerative Colitis

The FDA is addressing concerns about tampon safety following a 2024 study that discovered metals in tampons during laboratory testing.
Some of the tampon makers include Procter &amp; Gamble Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>), and Kimberly-Clark Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>).
A&nbsp;<a target="_blank" href="https://www.sciencedirect.com/science/article/pii/S0160412024004355" rel="noreferrer noopener">study</a> published in July&nbsp;found a variety of metals, including arsenic, &nbsp;cadmium, and lead, in more than&nbsp;a dozen brands of tampons.
The researchers said they evaluated the concentrations of 16 metal(loid)s in 30 tampons from 14 tampon brands and 18 product lines.
The FDA reassured the public that all tampons must meet strict safety and effectiveness requirements before they can be legally sold in the U.S. Tampon manufacturers are required to conduct thorough tests of their products and component materials throughout the manufacturing process.
This includes pre-market biocompatibility testing, which the FDA evaluates.
While the study identified the presence of metals in certain tampons, it did not examine whether these metals are released during use or absorbed by the vaginal lining, nor did it explore the potential for metals entering the bloodstream.
In response, the FDA has <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-regulatory-science-research-programs-conducted-osel/biocompatibility-and-toxicology-program-research-medical-devices-biocompatibility-and-toxicology" rel="noreferrer noopener">launched</a> two initiatives to investigate the issue further.
<ul>
<li>First, the FDA has commissioned an independent review of the available literature on tampon safety. This review aims to enhance the agency&#8217;s understanding of existing data on the chemicals found in tampons and any associated health risks.</li>
<li>Second, the FDA has begun its internal laboratory study to measure how much metals are released from tampons under conditions mimicking typical use.</li>
</ul>
The findings from these studies will contribute to a comprehensive risk assessment of metal exposure from tampons. The FDA plans to share the results of its literature review and lab tests with the public once they have been peer-reviewed.
Additionally, the FDA emphasized that it will continue to monitor tampon safety as part of its total product lifecycle approach to medical devices.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40819405/adobe-shakes-up-video-editing-with-ai-powered-creation-tools-whats-on-the-cards" target="_blank" rel="noreferrer noopener">Adobe Shakes Up Video Editing With AI-Powered Creation Tools &#8211; What&#8217;s On The Cards?</a></li>
</ul>
Photo by Klymenko Mariia via shutterstock

Media

Metals in Tampons: FDA Initiates New Safety Measures and Testing

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is reportedly facing a lawsuit for allegedly using copyrighted instrumental music without permission in numerous YouTube and Facebook videos.
The legal action, filed by Associated Production Music (APM) in a Los Angeles federal court, accuses the pharmaceutical giant of &#8220;rampant infringement&#8221; involving nearly 80 videos featuring unlicensed tracks.
These videos were distributed online without obtaining proper music licenses from APM, which specializes in producing music for various media.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40813730/johnson-johnsons-mid-stage-lung-cancer-trial-reveals-fewer-infusion-related-reactions" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions</a>
APM, a joint venture between Sony Music Publishing and Universal Music Publishing, claims that despite repeated attempts to notify Johnson &amp; Johnson of the unlicensed use, the company neither obtained the necessary licenses nor acknowledged any wrongdoing, the Billboard <a target="_blank" href="https://www.billboard.com/pro/johnson-and-johnson-lawsuit-unlicensed-music-videos/" rel="noreferrer noopener">report</a> adds.
According to APM, Johnson &amp; Johnson failed to secure authorization to synchronize APM&#8217;s music with the videos in question, violating copyright law.
The lawsuit highlights the scope of the infringement, listing 30 different APM songs used by Johnson &amp; Johnson. The legal action suggests that even though these songs are not mainstream hits, using them without a license could lead to significant financial penalties.
Under federal copyright law, Johnson &amp; Johnson could face substantial damages. If the court finds that the company&#8217;s actions were willful, the pharmaceutical firm could be fined up to $150,000 per song, amounting to nearly $12 million for the 79 videos involved.
Price Action: JNJ stock is down 1.50% at $164.87 at the last check on Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40819204/boeings-production-delays-not-unexpected-analyst-says" target="_blank" rel="noreferrer noopener">Boeing&#8217;s Production Delays Not Unexpected, Analyst Says</a>.</li>
</ul>
Photo via Shutterstock

Sony Music-Universal Music JV Hits Johnson & Johnson With Copyright Lawsuit Over Unlicensed Music Use Covering 80 Videos

Tuesday,&nbsp;Johnson &amp; Johnson&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions (IRRs) with intravenous (IV) Rybrevant&nbsp;(amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40804959/dexamethasone-reduces-infusion-related-reactions-in-patients-with-egfr-mutated-non-small-cell-lung" rel="noreferrer noopener">L858R substitution mutations</a>.
Data were presented at the&nbsp;International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC).
The 40-patient study showed that prophylaxis with 8-mg dexamethasone taken for two days before the first infusion met the primary endpoint of incidence of IRRs at Cycle 1 Day 1 (C1D1), with an all-grades IRR rate for IV Rybrevant&nbsp;of 22.5%.
This represents a three-fold reduction in the incidence of IRRs compared to standard management of IRRs with IV Rybrevant, where historical data has observed an all-grades incidence rate of 67.4%.
All IRRs were mild or moderate (Grade 1 or 2), with no patients requiring hospitalization due to IRRs. No Grade 3 or higher IRR events were reported.
Over the last weekend, Johnson &amp; Johnson&nbsp;presented longer follow-up data from the landmark Phase 3 MARIPOSA study which showed first-line treatment with Rybrevant combined with Lazcluze (lazertinib) provided consistent benefit across long-term outcomes compared to osimertinib monotherapy in adult NSCLC patients with EGFR exon 19 deletions or <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40764394/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-show-strong-favorable-overall-survival-trend-v" rel="noreferrer noopener">L858R substitution mutations</a>.
The data show a strong and improving overall survival (OS) trend favoring Rybrevant plus Lazcluze at approximately three years of follow-up.
<ul>
<li>61% of patients receiving Rybrevant plus Lazcluze&nbsp;were alive compared to 53% of those treated with osimertinib (Median OS not estimable vs 37.3 months).</li>
</ul>
Overall survival will continue to be assessed with longer term follow-up as a key secondary endpoint.
Results further showed Rybrevant plus Lazcluze demonstrated a trend toward improved central nervous system disease control compared to osimertinib at three years.
<ul>
<li>Intracranial PFS was double for Rybrevant plus Lazcluzeversus osimertinib (38% vs. 18%, respectively).</li>
</ul>
More patients remained on treatment with the Rybrevant plus Lazcluze combination compared to osimertinib (40% vs. 29%).
Additionally, more patients receiving Rybrevant plus Lazcluze at the three-year follow-up had not started a subsequent therapy versus osimertinib (45% vs. 32%).
Progression-free survival after the first subsequent therapy was 57% for Rybrevant plus Lazcluze combination compared to 49% for osimertinib.
In&nbsp;August 2024, the FDA approved Rybrevant plus Lazcluze following a Priority Review as a first-line therapy for patients with&nbsp;EGFR-mutated NSCLC based on the favorable efficacy and safety profile demonstrated in this study.
Price Action: JNJ stock is up 0.09% at $167.53 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40812280/at-t-ceo-john-stankey-flags-normalizing-wireless-trends-and-strong-fiber-growth-details" target="_blank" rel="noreferrer noopener">AT&amp;T CEO John Stankey Flags Normalizing Wireless Trends And Strong Fiber Growth: Details</a>.</li>
</ul>
Photo: Shutterstock

Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Viatris

Zoetis

RBC Capital

Cantor Fitzgerald

Daiwa Capital

Goldman Sachs

TD Cowen

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Johnson & Johnson

Johnson & Johnson (JNJ) Forecast

Johnson & Johnson (NYSE:JNJ) Stock, Quote.Headers.trade-ideas